COMMUNIQUÉS West-GlobeNewswire
-
FDA Clears OsteoProbe® (K250216): First-Ever Device Indication for Measuring Bone Material Strength
30/09/2025 -
STRATA Skin Sciences Receives Continued Validation for its Personalized Approach with New Published Study Highlighting XTRAC® Excimer Laser Treatment Combined with a Topical Drug in Psoriasis
30/09/2025 -
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
30/09/2025 -
Mainz Biomed to Present the Future of Colorectal Cancer Screening at WEO CRC Screening Committee Meeting
30/09/2025 -
gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
30/09/2025 -
Medera Strengthens Leadership Team with Three Key Executive Appointments
30/09/2025 -
SCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)
30/09/2025 -
HNL Lab Medicine Introduces Self-Collected HPV Test to Increase Privacy and Access
30/09/2025 -
Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases
30/09/2025 -
Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
30/09/2025 -
Acentra Health’s Dr. Ryan Bosch Named a 2025 Innovator in Health Care by Washington Business Journal
30/09/2025 -
Thousands of State of Georgia employees walk 880 million steps to benefit Title I schools
30/09/2025 -
Parexel Announces AI Partnership with Weave Bio to Accelerate Regulatory Submission Processes
30/09/2025 -
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
30/09/2025 -
24/7 Market News: Sportswear and Smart Textiles are likely Key Spider Silk Target Markets for Kraig Labs
30/09/2025 -
PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress
30/09/2025 -
Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer
30/09/2025 -
Coloplast A/S - Financial Calendar 2025-26
30/09/2025 -
The MUHC Foundation’s Inaugural Breakthrough Run Wins Big at the Montreal Marathon
30/09/2025
Pages